Cargando…
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrosp...
Autores principales: | Hendricks, Alexander, Amallraja, Anu, Meißner, Tobias, Forster, Peter, Rosenstiel, Philip, Burmeister, Greta, Schafmayer, Clemens, Franke, Andre, Hinz, Sebastian, Forster, Michael, Williams, Casey B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072525/ https://www.ncbi.nlm.nih.gov/pubmed/32046290 http://dx.doi.org/10.3390/cancers12020393 |
Ejemplares similares
-
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy
por: Hendricks, Alexander, et al.
Publicado: (2020) -
Identifying patients with an unfavorable prognosis in early stages of colorectal carcinoma
por: Hendricks, Alexander, et al.
Publicado: (2018) -
Case report: 16-yr life history and genomic evolution of an ER(+) HER2(−) breast cancer
por: Xu, Bing, et al.
Publicado: (2020) -
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
por: Meißner, Tobias, et al.
Publicado: (2017) -
Longitudinal Analysis of Circulating Tumor Cells in Colorectal Cancer Patients by a Cytological and Molecular Approach: Feasibility and Clinical Application
por: Hendricks, Alexander, et al.
Publicado: (2021)